Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Clinical treatment programs – US	$ 40	$ 49
Total Revenues	40	49
Costs and Expenses:
Production costs	8
Research and development	1,951	2,052
General and administrative	3,815	2,292
Total Costs and Expenses	5,774	4,344
Operating loss	(5,734)	(4,295)
Gain (Loss) on investments	(92)	203
Interest and other income	81	199
Interest Expense and Other Finance Costs	(72)
(Loss) on sale of assets		(23)
Gain from sale of income tax operating losses		255
Net Loss	$ (5,817)	$ (3,661)
Basic loss per share	$ (0.12)	$ (0.08)
Diluted loss per share	$ (0.12)	$ (0.08)
Weighted average shares outstanding basic	49,458,023	48,399,950
Weighted average shares outstanding diluted	49,458,023	48,399,950